Stay up to date with notifications from The Independent

Notifications can be managed in browser preferences.

Drugs firm challenges sleeping tablet ban

Liz Hunt,Medical Correspondent
Thursday 24 June 1993 18:02 EDT
Comments

Your support helps us to tell the story

From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.

At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.

The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.

Your support makes all the difference.

UPJOHN LTD, manufacturer of the banned sleeping pill Halcion, is to seek a judicial review of the Government's decision not to allow the tablets back on pharmacy shelves, and to revoke the drug's licence.

It is believed to be the first time a pharmaceutical company has taken such action on a licensing matter. The outright ban on the drug, once the biggest selling sleeping tablet in the world, followed conflicting evidence on its safety.

Ley S Smith, president and chief operating officer of the US company, said Upjohn regretted taking such 'drastic' action, but 'the public deserves to know why the licensing authority rejected expert scientific advice given to it under British law'.

Halcion, also known as triazolam, has been linked with cases of amnesia, paranoia, suicide and murder and was withdrawn at 24 hours' notice in October 1991 by the Committee on Safety of Medicines (CSM), the body that advises ministers on drug licensing. An appeal to the CSM was later upheld, but the Medicines Commission, said that the drug should be available at lower doses.

An expert committee found in April this year that the drug was not a 'significant hazard' and its benefits outweighed the risks.

However, earlier this month Brian Mawhinney, the health minister, said the licence would be revoked and that 'it was right to be cautious.'

Mr Smith said that Halcion was safe when used appropriately. 'We believe that there are insufficient grounds for the licensing authority's actions.'

Join our commenting forum

Join thought-provoking conversations, follow other Independent readers and see their replies

Comments

Thank you for registering

Please refresh the page or navigate to another page on the site to be automatically logged inPlease refresh your browser to be logged in